ClinicalTrials.gg
Active, not recruitingNCT06161441Updated Aug 10, 2026

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

A Phase 2 interventional study of Fianlimab and Cemiplimab in Resectable Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 123 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Enrollment
5th of 18
195 · median 86
Started
2024
with 2 others
Phase 2
7 of 21
1 open now
Primary completion
2026-08
later than 1 of 10 live
Registered
17th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery.

The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How much of each study drug is in the blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
  • How administering the study drugs might affect quality of life
03

Conditions studied

  • Resectable Non-small Cell Lung Cancer

Keywords

  • Stage II to IIIB (N2)
  • NSCLC
  • Neoadjuvant therapy
  • Subsequent adjuvant therapy
  • PeriOperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients with newly diagnosed, confirmed, fully resectable stage II to IIIB (N2) NSCLC as per American Joint Committee on Cancer (AJCC) version 8
  2. For patients with evidence of mediastinal adenopathy on imaging, mediastinal lymph node sampling is required as defined in the protocol
  3. All patients must have disease status showing no evidence of distant documented by a complete physical examination and imaging studies performed within 4 weeks prior to randomization as defined in the protocol
  4. A patient must have an evaluable Programmed cell death ligand-1 () immunohistochemistry (IHC) result as defined in the protocol
  5. (ECOG) performance status of 0 or 1
  6. Adequate bone marrow, hepatic and kidney function as defined in the protocol

Key Exclusion Criteria:

  1. Any evidence of locally advanced unresectable or metastatic disease as defined in the protocol
  2. Patients with tumors with known Epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations as defined in the protocol
  3. Uncontrolled infection with (HIV), (HBV) or virus (HCV) infection as defined in the protocol
  4. Treatment with anti-cancer therapy including immunotherapy, chemotherapy, radiotherapy, or biological therapy in the 3 years prior to randomization. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive cancers in long term remission is allowed.
  5. Patients with a history of myocarditis

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Arm A

    Randomized 1:1:1 Neoadjuvant period: placebo + cemiplimab + platinum doublet chemotherapy Adjuvant period: placebo + cemiplimab

    Drug: Cemiplimab · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Carboplatin · Drug: Cisplatin · Drug: Placebo

  • Experimental
    Arm B

    Randomized 1:1:1 Neoadjuvant period: fianlimab high dose + cemiplimab + platinum doublet chemotherapy Adjuvant period: fianlimab high dose + cemiplimab

    Drug: Fianlimab · Drug: Cemiplimab · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Arm C

    Randomized 1:1:1 Neoadjuvant period: fianlimab low dose + cemiplimab + platinum doublet chemotherapy Adjuvant Period: fianlimab low dose + cemiplimab

    Drug: Fianlimab · Drug: Cemiplimab · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Administered intravenously (IV) every 3 weeks (Q3W)

    Also known as: REGN3767

  • Administered IV Q3W

    Also known as: REGN2810, Libtayo

  • Administered IV Q3W

    Also known as: Alimta

  • Administered IV Q3W

    Also known as: Taxol

  • Administered IV Q3W

    Also known as: Paraplatin

  • Administered IV Q3W

    Also known as: Platinol

  • DrugPlacebo

    Administered IV Q3W

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samples

    Time frame: Up to 24 months

Secondary outcomes

  1. Event-Free Survival (EFS)

    Time frame: Up to 3 years

  2. Major pathological response (MPR) by BIPR in post-treatment resected tumor samples

    Time frame: Up to 24 months

  3. MPR by local pathology review in post-treatment resected tumor samples

    Time frame: Up to 24 months

  4. Tumor response to neoadjuvant therapy per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria by investigator assessment

    Time frame: Up to 24 months

  5. Occurrence of Adverse events (AEs)

    Time frame: Up to 5 years

  6. Occurrence of Treatment-emergent adverse event (TEAEs)

    Time frame: Up to 5 years

  7. Occurrence of Serious adverse events (SAEs)

    Time frame: Up to 5 years

  8. Occurrence of Adverse events of special interest (AESIs)

    Time frame: Up to 5 years

  9. Occurrence of immune-mediated adverse events (imAEs)

    Time frame: Up to 5 years

  10. Occurrence of interruption and discontinuation of study drug(s) due to TEAE

    Time frame: Up to 5 years

  11. Occurrence of laboratory abnormalities

    Grade ≥3 per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) including standard hematology, chemistry, urinalysis, and other lab tests

    Time frame: Up to 5 years

  12. Occurrence of death due to TEAE

    Time frame: Up to 5 years

  13. Concentrations of cemiplimab in serum

    Time frame: Up to 30 months

  14. Concentrations of fianlimab in serum

    Time frame: Up to 30 months

  15. Anti-drug antibodies (ADA) to fianlimab in serum over time

    Time frame: Up to 30 months

  16. ADA to cemiplimab in serum over time

    Time frame: Up to 30 months

  17. Percentage of patients with definitive surgery

    Time frame: Up to 24 months

  18. Percentage of patients with cancelled surgery

    Time frame: Up to 24 months

  19. Percentage of patients with delayed surgery

    Time frame: Up to 24 months

  20. Completeness of resection (R0, R1, R2, Rx)

    Time frame: Up to 24 months

  21. Length in delay of surgery

    Time frame: Up to 24 months

  22. Type of surgery (lobectomy, sleeve lobectomy, bilobectomy, pneumonectomy, other)

    Time frame: Up to 24 months

  23. Median length of hospital stay

    Time frame: Up to 24 months

  24. Surgical approach (thoracotomy, minimally invasive, minimally invasive to thoracotomy)

    Time frame: Up to 24 months

  25. Incidence of peri operative AE associated with surgery

    Time frame: Up to 90 days post-surgery

  26. Incidence of peri operative SAE associated with surgery

    Time frame: Up to 90 days post-surgery

  27. Incidence of post operative AE associated with surgery

    Time frame: Up to 90 days post-surgery

  28. Incidence of post operative SAE associated with surgery

    Time frame: Up to 90 days post-surgery

  29. Overall change in patient-reported global health status/QoL per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Up to 5 years

  30. Overall change in patient-reported physical functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  31. Overall change in patient-reported role functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  32. Overall change in patient-reported chest pain per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented. A lower score indicates a better outcome.

    Time frame: Up to 5 years

  33. Overall change in patient-reported dyspnea per EORTC QLQ-LC13

    Time frame: Up to 5 years

  34. Overall change in patient-reported cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  35. Overall change in patient-reported composite of chest pain, dyspnea, and cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  36. Change in patient-reported general health status per EuroQoL 5-Dimensional 5-Level Scale (EQ-5D-5L) index

    The EQ-5D-5L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale: no problems, slight problems, moderate problems, severe problems and extreme problems

    Time frame: Up to 5 years

  37. Change in patient-reported general health status per Visual analogue scale (VAS) scores

    The EQ-5D-5L VAS records the respondent's self-rated health on a 10 centimeter (cm) vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine".

    Time frame: Up to 5 years

  38. Time until definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30

    Time frame: Up to 5 years

  39. Time until definitive deterioration in patient-reported physical functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  40. Time until definitive deterioration in patient-reported role functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  41. Time until definitive deterioration in patient-reported chest pain per EORTC QLQ-LC13

    Time frame: Up to 5 years

  42. Time until definitive deterioration in patient-reported dyspnea per EORTC QLQ-LC13

    Time frame: Up to 5 years

  43. Time until definitive deterioration in patient-reported cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  44. Time until definitive deterioration in patient-reported composite of chest pain, dyspnea and cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

07

Study locations

123 sites

Showing the first 100 of 123 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2026, 25 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 25 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 7, 2023
StartActual
Jul 16, 2024
Primary completionEst.
Aug 24, 2026
CompletionEst.
Nov 4, 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06161441
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Jul 16, 2024
Primary completion
Aug 24, 2026 (estimated)
Completion
Nov 4, 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fianlimab

Start the discussion